The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Clinical Experience with Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers
Abstract
Angiogenesis is required for tumor growth and metastasis and, therefore, represents an exciting target for cancer treatment. Angiogenesis is a complex process that is tightly regulated by pro- and anti-angiogenic growth factors. Physiologic angiogenesis takes place during tissue growth and repair, during the female reproductive cycle, and during fetal development. Pathologic angiogenesis is characterized by either excessive (eg, cancer) or inadequate (eg, coronary artery disease) neovascularization. Angiogenesis occurs in a series of complex and interrelated steps that involve the release of pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF). VEGF regulates both vascular proliferation and permeability, and functions as an anti-apoptotic factor for newly formed blood vessels. The biological effects of VEGF are mediated by two receptors, VEGF-1 and VEGF-2, whose expression is largely limited to the vascular endothelium. VEGF is often expressed in tumors at substantially increased levels. It is expressed in response to hypoxia, oncogenes, and other cytokines, and its expression is associated with poor prognosis in several types of cancer. Several different strategies have been used to inhibit VEGF, including anti-VEGF monoclonal antibodies (eg, bevacizumab) and agents that inhibit the VEGF receptor (eg, SU5416). Both types of agents have tolerable side effects and have shown promise when evaluated in a wide range of tumor types. Angiogenesis, the role of VEGF in angiogenesis and malignancy, and strategies for cancer treatment with VEGF inhibitors are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., & Gasparini, G. (1992) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1875 · Cited by 1,775
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Weidner, N., Carroll, P. R., Flax, J. D., Blumenfeld, W., & Folkman, J. (1993) · PubMed Central · Cited by 1,620
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Roberts, W. G., & Palade, G. E. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2369 · Cited by 1,033
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Liotta, L. A., Kleinerman, J. I., & Saidel, G. M. (1974) · PubMed · Cited by 766
Kendall, R. L., Wang, G., & Thomas, K. A. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1355 · Cited by 724
Vascular endothelial growth factor and its receptors
Klagsbrun, M., & A. D'Amore, P. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00027-5 · Cited by 682
Shweiki, D., Neeman, M., Itin, A., & Keshet, E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.768 · Cited by 599
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer
Valtola, R., Salven, P., Heikkilä, P., Taipale, J., Joensuu, H., Rehn, M., Pihlajaniemi, T., Weich, H., deWaal, R., & Alitalo, K. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65392-8 · Cited by 541
VEGF Receptor Signaling in Tumor Angiogenesis
McMahon, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-3 · Cited by 519
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
Kieser, A., Weich, H. A., Brandner, G., Marmé, D., & Kölch, W. (1994) · PubMed · Cited by 511
Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.139 · Cited by 494
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Toi, M., Hoshina, S., Takayanagi, T., & Tominaga, T. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02904.x · Cited by 391
Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 364
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Toi, M., Inada, K., Suzuki, H., & Tominaga, T. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666040 · Cited by 362
Eggert, A., Ikegaki, N., Kwiatkowski, J. L., Zhao, H., Brodeur, G. M., & Himelstein, B. P. (2000) · PubMed · Cited by 353
Form, D. M., & Auerbach, R. (1983) · Experimental Biology and Medicine · doi:10.3181/00379727-172-41548 · Cited by 341
Adams, J., Carder, P. J., Downey, S. E., Forbes, M. A., MacLennan, K. A., Allgar, V. L., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., et al. (2000) · PubMed · Cited by 339
Ishigami, S.-I., Arii, S., Furutani, M., Niwano, M., Harada, T., Mizumoto, M., Mori, A., Onodera, H., & Imamura, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.688 · Cited by 338
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., & Ellis, L. M. (1999) · PubMed · Cited by 334
Geng, L., Donnelly, E. F., McMahon, G., Lin, P. C., Sierra‐Rivera, E., Oshinka, H., & Hallahan, D. E. (2001) · PubMed · Cited by 334
Brekken, R. A., Overholser, J. P., Stastny, V., Waltenberger, J. L., Minna, J. D., & Thorpe, P. E. (2000) · PubMed · Cited by 331
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329
Drake, C. J., & Little, C. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7657 · Cited by 324
Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B., & Albitar, M. (1999) · Blood · doi:10.1182/blood.v94.11.3717 · Cited by 319
Mattern, J., Koomägi, R., & Volm, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.166 · Cited by 309
Drake, C. J., Cheresh, D. A., & Little, C. D. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.7.2655 · Cited by 307
Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B., & Albitar, M. (1999) · Blood · doi:10.1182/blood.v94.11.3717.423k09_3717_3721 · Cited by 299
Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya, M., & Sato, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203533 · Cited by 285
Tsai, J.-C., Goldman, C. K., & Gillespie, G. Y. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.82.5.0864 · Cited by 278
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
Linderholm, B., Tavelin, B., Grankvist, K., & Henriksson, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3121 · Cited by 264
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher, B. A., Sotomayor, E. A., & Huang, Z. D. (1992) · PubMed · Cited by 260
Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., & Henriksson, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1423 · Cited by 254
Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites
Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0373-0 · Cited by 254
Mendel, D. B., Laird, A., Smolich, B. D., Blake, R., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., et al. (2000) · PubMed · Cited by 230
Zebrowski, B. K., Yano, S., Liu, W., Shaheen, R. M., Hicklin, D. J., Putnam, J. B., & Ellis, L. M. (1999) · PubMed · Cited by 223
Pleural diseases related to metastatic malignancies
Sahn, S. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10081907 · Cited by 222
Eppenberger, U., Kueng, W., Schlaeppi, J. M., Roesel, J. L., Benz, C., Mueller, H., Matter, A., Zuber, M., Luescher, K., Litschgi, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3129 · Cited by 218
Mendel, D. B., Schreck, R., West, D. C., Li, G., Strawn, L. M., Tanciongco, S. S., Vasile, S., Shawver, L. K., & Cherrington, J. M. (2000) · PubMed · Cited by 215
Cascinu, S., Staccioli, M. P., Gasparini, G. M., Giordani, P., Catalano, V., Ghiselli, R., Rossi, C., Baldelli, A. M., Graziano, F., Saba, V., et al. (2000) · PubMed · Cited by 208
Lin, P. C., Sankar, S., Shan, S. Q., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., & Peters, K. G. (1998) · PubMed · Cited by 199
Borgström, P., Gold, D. P., Hillan, K. J., & Ferrara, N. (1999) · PubMed · Cited by 196
New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
(2000) · Advances in Cancer Research · doi:10.1016/s0065-230x(00)79001-4 · Cited by 193
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Curwen, J., Hennequin, L. F., Thomas, A., Stokes, E. S. E., Curry, B. J., Richmond, G., et al. (2000) · PubMed · Cited by 192
Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site
Fairbrother, W. J., Christinger, H. W., Cochran, A. G., Fuh, G., Keenan, C. J., Quan, C., Shriver, S. K., Tom, J. Y. K., Wells, J. A., & Cunningham, B. C. (1998) · Biochemistry · doi:10.1021/bi981931e · Cited by 190
Akagi, Y., Liu, W., Zebrowski, B. K., Xie, K., & Ellis, L. M. (1998) · PubMed · Cited by 184
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Ohta, Y., Endo, Y., Tanaka, M., Shimizu, J., Oda, M., Hayashi, Y., Watanabe, Y., & Sasaki, T. (1996) · PubMed · Cited by 183
Torimura, T., Sata, M., Ueno, T., Kin, M., Tsuji, R., Suzaku, K., Hashimoto, O., Sugawara, H., & Tanikawa, K. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90205-2 · Cited by 176
Imoto, H., Osaki, T., Taga, S., Ohgami, A., Ichiyoshi, Y., & Yasumoto, K. (1998) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(98)70398-8 · Cited by 171
Vajkoczy, P., Menger, M. D., Vollmar, B., Schilling, L., Schmiedek, P., Hirth, K. P., Ullrich, A., & Fong, T. A. T. (1999) · Neoplasia · doi:10.1038/sj.neo.7900006 · Cited by 161
Loncaster, J. A., Cooper, R. A., Logue, J. P., Davidson, S. E., Hunter, R. D., & West, C. M. L. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1319 · Cited by 160
Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K., & Henriksson, R. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000120)89:1<51::aid-ijc9>3.0.co;2-8 · Cited by 158
Tumour vasculature as a target for anticancer therapy
Eatock, M. M., Schätzlein, A. G., & Kaye, S. B. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0158 · Cited by 150
Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., & Bergh, J. C. S. (2001) · PubMed · Cited by 149
Mineta, H., Miura, K., Ogino, T., Takebayashi, S., Misawa, K., Ueda, Y., Suzuki, I., Dictor, M. R., Borg, Å., & Wennerberg, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1357 · Cited by 134
Serum VEGF levels in women with a benign breast tumor or breast cancer
Salvén, P., Perhoniemi, V. J., Tykkä, H., Mäenpää, H. O., & Joensuu, H. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006178517505 · Cited by 114
Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation
Verheul, H. M. W., Hoekman, K., Jorna, A. S., Smit, E. F., & Pinedo, H. M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-45 · Cited by 111
Hirai, M., Nakagawara, A., 大崎, 達., Hayashi, Y., Hirono, M., & Yoshihara, T. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6056 · Cited by 109
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.
Arora, N., Masood, R., Zheng, T. Z., Cai, J., Smith, D. L., & Gill, P. S. (1999) · PubMed · Cited by 107
Schlaeppi, J.-M., & Wood, J. M. (1999) · Cancer and Metastasis Reviews · doi:10.1023/a:1006358220123 · Cited by 105
Angelov, L., Salhia, B., Roncari, L., McMahon, G., & Guha, A. (1999) · PubMed · Cited by 105
Fontanini, G., Boldrini, L., Vignati, S., Chinè, S., Basolo, F., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., & Bevilacqua, G. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10145-9 · Cited by 100
Dor, Y., & Keshet, E. (1997) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(97)00091-1 · Cited by 100
Zhu, Z., & Witte, L. (1999) · Investigational New Drugs · doi:10.1023/a:1006314501634 · Cited by 93
Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β
Akagi, Y., Liu, W., Xie, K., Zebrowski, B. K., Shaheen, R. M., & Ellis, L. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690553 · Cited by 88
Xw, B., Ll, D., Jq, S., Ys, C., & Fx, L. (2000) · PubMed · Cited by 64
Castilla, M. Á., Caramelo, C. A., Gazapo, R., Martín‐Belloso, O., González‐Pacheco, F. R., Tejedor, A., Bragado, R., & Arroyo, M. V. A. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00693-7 · Cited by 52
Regulation of Angiogenesis by Controlling VEGF Receptor
Murota, S., Onodera, M., & Morita, I. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06315.x · Cited by 36
Greb, R. R., Maier, I., Wallwiener, D. R., & Kiesel, L. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690681 · Cited by 34
Cited by
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Frank, R. N. (2004) · New England Journal of Medicine · doi:10.1056/nejmra021678 · Cited by 891
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Metadata
- Authors
- Rosen, L. S.
- Venue
- Cancer Control
- Publisher
- SAGE Publications
- Published
- 2002-03
- Volume
- 9
- Issue
- 2_suppl
- Pages
- 36-44
- ISSN
- 1073-2748 (ISSN-L)
- OpenAlex
- W2185838453
- Cited by
- 268
- References
- 95
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.